▶ 調査レポート

発熱性物質試験の世界市場:試験の種類別(リムルス変形細胞溶解物(LAL)試験、ラビット発熱性物質試験、単球活性化試験、その他)、用途別(注射、ワクチン、タブレット、医療機器、その他)、エンドユーザー別、地域別分析

• 英文タイトル:Global Pyrogen Testing Market - Segmented by Test Type, Application, End User and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。発熱性物質試験の世界市場:試験の種類別(リムルス変形細胞溶解物(LAL)試験、ラビット発熱性物質試験、単球活性化試験、その他)、用途別(注射、ワクチン、タブレット、医療機器、その他)、エンドユーザー別、地域別分析 / Global Pyrogen Testing Market - Segmented by Test Type, Application, End User and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08486資料のイメージです。• レポートコード:B-MOR-08486
• 出版社/出版日:Mordor Intelligence / 2018年5月15日
• レポート形態:英文、PDF、108ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥450,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥477,000 (USD4,500)▷ お問い合わせ
  Corporate User¥927,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、発熱性物質試験の世界市場について調べ、発熱性物質試験の世界規模、市場動向、市場環境、試験の種類別(リムルス変形細胞溶解物(LAL)試験、ラビット発熱性物質試験、単球活性化試験、その他)分析、用途別(注射、ワクチン、タブレット、医療機器、その他)分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・発熱性物質試験の世界市場インサイト
・発熱性物質試験の世界市場環境
・発熱性物質試験の世界市場動向
・発熱性物質試験の世界市場規模
・発熱性物質試験の世界市場規模:試験の種類別(リムルス変形細胞溶解物(LAL)試験、ラビット発熱性物質試験、単球活性化試験、その他)
・発熱性物質試験の世界市場規模:用途別(注射、ワクチン、タブレット、医療機器、その他)
・発熱性物質試験の世界市場規模:エンドユーザー別
・発熱性物質試験の世界市場:地域別市場規模・分析
・発熱性物質試験の北米市場規模・予測
・発熱性物質試験のアメリカ市場規模・予測
・発熱性物質試験のヨーロッパ市場規模・予測
・発熱性物質試験のアジア市場規模・予測
・発熱性物質試験の日本市場規模・予測
・発熱性物質試験の中国市場規模・予測
・発熱性物質試験のインド市場規模・予測
・発熱性物質試験の韓国市場規模・予測
・関連企業情報・競争状況

The pyrogen testing market is expected to register a growth rate of nearly 12.5% during the forecast period, 2018 – 2023. Pyrogen testing refers to the process of determining microbes or their metabolites presence in drugs and intravenous solutions during their manufacture, which is expected to grow steadily primarily driven by increased demand for these products in pharmaceutical and biotechnology industry and rising investments in research and development. The presence of well-developed healthcare infrastructure, well-defined rules and regulations for pharmaceutical manufacturing process should help North America to dominate the market share in the forecast period.

Growing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases is one of the primary factors driving the pyrogen testing market. The pyrogen testing has been found to be highly effective in case of airborne diseases such as chronic obstructive lung diseases and childhood asthma, where it quantitively assess the human-relevant airborne pyrogens. These tests are further highly useful in detecting contamination related to an inflammatory response in cases of chronic kidney disorders. The chronic diseases prevalence is high in developed countries and is growing at a high in emerging markets. Thus, the demand for pyrogen testing with increasing awareness should raise this market in the forecast period.
Other factors driving this market are high investments in research and development in the life science industry, the rise in the number of pharmaceutical and biotechnological companies and rise in the launch of biological products, and surge in new innovative drugs.

Stringent Government Regulations for Pyrogen Testing

The strict regulatory norms in the pharmaceutical industry is one of the primary factors restraining the growth of this market. The regulatory issues are majorly concerned with the differences in the functioning of big pharmaceutical companies and small companies which do not have enough budget and resources, and thus, have issues related to cross contamination, manipulation of genetically modified organisms and corresponding facility design issues particularly for the biologically derived medical products. Thus, the regulatory issues concerned with the manufacturing of drugs and biologics and involvement of pyrogen testing restricts the growth of this market.
Other factors limiting the growth of this market are reimbursement issues and rising pressure in regards to adoption of animal-free testing methods.

US is Expected to have Largest Share in the Market

The United States is expected to dominate the market share with well-established healthcare infrastructure, better regulatory framework, and government support and presence of many large biotechnological and biopharmaceutical firms, such as Roche, Merck, Amgen, and Celegene, among others. These companies have a high focus on new drug and biologics development with continuous support from the government in form of funding from several government bodies and investors, which fuel the growth of this market. Asia Pacific is expected to exhibit the highest growth rate. The healthy CAGR is expected due to rising healthcare expenditure in countries, such as India, China and Japan. This is accompanied by lesser stringency in government regulations for drug development.

Key Developments in the Market

• January 2018 – Bell Biosystems presented the results of their latest pre-clinical safety of intravascularly injected stem cells labeled for MRI tracking using a high dose of Bell’s Magnelle(R) brand MRI contrast agent, as per the USP 151 pyrogenicity guidelines

Major players: ASSOCIATES OF CAPE COD, INC, CHARLES RIVER LABORATORIES INTERNATIONAL, INC, ELLAB A/S, GENSCRIPT, HYGLOS GMBH, LONZA, MERCK KGAA, SANQUIN, THERMO FISHER SCIENTIFIC, INC, AND WUXI APPTEC, amongst others.

Reasons to Purchase this Report

• Current and future of pyrogen testing market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Market Dynamics
6.1 Market Drivers
6.1.1 Increasing Prevalence of Chronic Disease
6.1.2 High Investments in Research and Development in the Life Science Industry
6.1.3 Rising number of Pharmaceutical and Biotechnological Companies
6.1.4 Launch of Biological Products and Surge in New Innovative Drugs
6.2 Market Restraints
6.2.1 Stringent Government Regulations
6.2.2 Rising Pressure in Regards to Adoption of Animal Free Testing Methods
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Test Type
7.1.1 Limulus Amebocyte Lysate (LAL) Test
7.1.1.1 Chromogenic test
7.1.1.2 Turbidimetric test
7.1.1.3 Gel clot test
7.1.2 Rabbit Pyrogen Test
7.1.3 Monocyte Activation Test
7.1.4 Others
7.2 By Application
7.2.1 Injections
7.2.2 Vaccines
7.2.3 Tablets
7.2.4 Medical Devices
7.2.5 Others
7.3 By End-user
7.3.1 Pharmaceutical and Biotechnology Companies
7.3.2 Medical Device Companies
7.3.3 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 US
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 UK
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of MEA
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Associates of Cape Cod, Inc
9.2 Charles River Laboratories International, Inc
9.3 Ellab A/S
9.4 GenScript
9.5 Hyglos GmbH
9.6 Lonza
9.7 Merck KGaA
9.8 Sanquin
9.9 Thermo Fisher Scientific, Inc
9.10 WuXi AppTec
9.11 List Not Exhaustive
10. Future Market Outlook